P/B
1,6
Z Squared
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
$213.9M
Market Cap • 10/16/2026
2018
(8 years)
Founded
2022
(4 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
76,5
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2,5
EPS
—
Market Cap
Market Cap
213,9M
EV
198,4M
EV/Revenue
70,9
EV/EBITDA
-9,8
EV/EBIT
-8,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-10,7%
Total Yield
-10,7%
Payout
0%
Retained Earnings
-13,7M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
8,4%
% Goodwill
79,5%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
127,3%
CAGR Net Income 5Y
34,8%
CAGR OCF 5Y
60,7%
Leverage
N.D./EBITDA
0,8
Debt/Equity
0%
Current Ratio
7,7
Quick Ratio
7,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!